A landmark Depo-Provera meningioma settlement 2026 has reshaped the landscape of pharmaceutical mass tort litigation. In June 2026, Pfizer agreed to a global settlement structured as a grid-based framework to resolve thousands of lawsuits filed by women who developed meningioma brain tumors after long-term use of the injectable contraceptive Depo-Provera. With more than 6,400 federal cases pending as of September 2026, this deal represents one of the most significant pharmaceutical injury resolutions of the decade — and it carries major implications for every claimant still waiting for justice.
What the June 2026 Depo-Provera Settlement Agreement Actually Means
The global settlement agreed to in June 2026 marks a pivotal turning point for women who suffered debilitating brain tumors linked to Depo-Provera, the injectable progestin-based contraceptive manufactured by Pfizer. Plaintiffs across the country have been filing lawsuits alleging that long-term use of the drug significantly elevated their risk of developing intracranial meningiomas — benign but potentially life-altering tumors that grow on the membranes surrounding the brain and spinal cord.
Pfizer and plaintiffs’ leadership formalized the agreement by signing a Master Settlement Agreement on July 21, 2026. The settlement is structured as a grid-based framework, meaning base compensation values are adjusted upward or downward depending on individual case factors such as the severity of injury, duration of Depo-Provera use, and other claimant-specific circumstances. The parties estimate that roughly 80 percent of the plaintiffs currently in the federal MDL will be eligible to participate.
The settlement announcement effectively removed the bellwether trial that had been scheduled for December 2026 from the court’s active docket. Bellwether trials are typically used in mass tort cases to gauge how juries respond to representative cases, and their removal signals that both sides have reached sufficient common ground to pursue a global resolution rather than continue through costly, drawn-out trial proceedings.
Settlement registration is expected to be completed in November 2026, with claims processing and the first settlement payments anticipated to begin during the first quarter of 2027. For individuals tracking the Depo-Provera meningioma settlement 2026, these deadlines are the most critical developments to monitor in the months ahead. You can track federal court filings and docket updates directly through the United States Courts official website.
The Science Behind the Claims: FDA Label Change and Meningioma Risk
The legal momentum behind the Depo-Provera meningioma settlement 2026 was significantly accelerated by a critical regulatory action in December 2025, when the U.S. Food and Drug Administration approved an update to the U.S. Prescribing Information for Depo-Provera, adding a warning about a potential increased risk of meningioma. That decision was grounded in a landmark study published in The BMJ that found women who used Depo-Provera long-term faced 5.6 times greater odds of developing an intracranial meningioma compared to non-users. This is not a marginal statistical finding — it represents a dramatic elevation in risk that plaintiffs argue Pfizer failed to adequately communicate to prescribing physicians and patients for years.
Meningiomas, while often classified as benign, can cause severe neurological symptoms including chronic headaches, vision problems, seizures, memory impairment, and in serious cases, may require invasive brain surgery. Women who underwent tumor resection frequently face lengthy recovery periods, cognitive deficits, and diminished quality of life — all of which form the foundation of damages claimed in this litigation. For those dealing with lasting neurological consequences, using a brain injury calculator can provide a preliminary estimate of what your claim may be worth based on your specific circumstances.
The FDA’s December 2025 label update was a watershed moment for plaintiffs. It provided official government acknowledgment of the meningioma risk — a validation that strengthened the evidentiary foundation of thousands of pending cases and almost certainly accelerated Pfizer’s willingness to reach a global resolution in the months that followed.
Key Statistics: Depo-Provera Meningioma Litigation at a Glance
Understanding the scale of this litigation helps claimants appreciate both the urgency and the complexity of the resolution process. Here are the most important numbers shaping the Depo-Provera meningioma settlement 2026:
- 6,400+ federal lawsuits pending as of September 2026
- 5.6x increased odds of meningioma among long-term Depo-Provera users, per The BMJ study
- December 2025 — FDA approved updated prescribing information adding a meningioma warning
- June 2026 — Pfizer agreed to a global grid-based settlement framework
- July 21, 2026 — Master Settlement Agreement signed by Pfizer and plaintiffs’ leadership
- ~80% of federal MDL plaintiffs estimated to be eligible for the settlement
- November 2026 — Settlement registration expected to be completed
- Q1 2027 — First settlement payments expected to begin
These figures underscore that this is one of the largest active pharmaceutical mass torts in the United States and that the resolution timeline is now clearly defined. Claimants who have not yet formally registered their interest with qualified legal counsel should treat the November 2026 registration deadline as an urgent priority.
How Damages in Depo-Provera Cases Compare to Other Pharmaceutical Verdicts
While specific individual payout amounts under the grid-based settlement framework have not yet been publicly disclosed, the structure of the agreement — with base values adjusted for individual case factors — is consistent with how other major pharmaceutical mass torts have been resolved. Cases involving more severe injuries, longer drug exposure, and greater documented impact on quality of life typically receive higher base values under grid frameworks of this type.
For context, comparable pharmaceutical mass tort settlements in recent years have produced individual payouts ranging from tens of thousands of dollars for less severe cases to several hundred thousand dollars or more for claimants who underwent brain surgery, experienced lasting neurological deficits, or suffered significant loss of earning capacity. The grid-based structure in the Depo-Provera settlement is designed to bring consistency and efficiency to that valuation process while still accounting for the meaningful differences between individual cases.
Factors that have historically influenced compensation in brain tumor and pharmaceutical injury cases include the number of Depo-Provera injections received, the duration of use, the size and location of the meningioma, whether surgery was required, the extent of post-operative complications, lost income, ongoing medical expenses, and the claimant’s age at the time of diagnosis. An experienced pharmaceutical injury attorney can help you understand where your specific case may fall within the settlement grid.
What Pending Claimants Should Know Right Now
If you are among the thousands of women who used Depo-Provera and were subsequently diagnosed with a meningioma, the period between now and the November 2026 registration deadline is critical. Here is what you need to understand about where things stand and what actions to prioritize:
The settlement registration window is approaching. With registration expected to close in November 2026, claimants who have not yet engaged with legal counsel may be at risk of missing the participation window. Approximately 80 percent of federal MDL plaintiffs are estimated to be eligible, but eligibility must be properly documented and submitted through the formal process.
Documentation is everything. The grid-based valuation framework means your compensation will be determined by your specific case facts. Medical records confirming your meningioma diagnosis, pharmacy and insurance records demonstrating your Depo-Provera use history, surgical records if applicable, and documentation of lost income or ongoing care needs are all essential. Begin gathering these materials immediately if you have not already done so.
Not participating carries risk. Claimants who choose to opt out of the settlement retain the right to pursue individual litigation, but doing so means forgoing the certainty of a negotiated resolution in favor of the uncertainty and expense of trial. Given that bellwether trials have been removed from the docket, the path to individual verdicts has become considerably longer and less predictable.
First payments are expected in early 2027. For claimants who complete registration by November 2026 and whose claims are processed promptly, the first settlement disbursements are anticipated to begin during the first quarter of 2027. This timeline gives claimants a concrete target to work toward.
Frequently Asked Questions About the Depo-Provera Meningioma Settlement 2026
Has the Depo-Provera meningioma settlement 2026 been fully finalized?
Yes. Pfizer and plaintiffs’ leadership signed a Master Settlement Agreement on July 21, 2026, formalizing the global resolution framework. The settlement is structured as a grid-based system with base compensation values adjusted for individual case factors. Settlement registration is expected to be completed in November 2026, and the first payments are anticipated in the first quarter of 2027. While the agreement is signed, the claims processing and distribution phase is still underway, so claimants should remain in close contact with their attorneys throughout this period.
How much money will claimants receive from the Depo-Provera settlement?
Specific individual payout amounts have not been publicly disclosed. The grid-based framework establishes base values that are then adjusted upward or downward based on factors specific to each claimant’s case, including the severity of the meningioma, duration of Depo-Provera use, whether surgery was required, post-operative complications, lost wages, and ongoing medical needs. Claimants with more severe injuries and longer documented drug exposure are generally expected to receive higher compensation values within the grid. Your attorney can provide a more tailored assessment once the full grid details are made available to participating counsel.
Who qualifies for the Depo-Provera meningioma settlement 2026?
Eligibility generally requires a documented history of Depo-Provera use and a confirmed diagnosis of intracranial meningioma. The parties estimate that approximately 80 percent of plaintiffs currently in the federal MDL will be eligible to participate. Additional eligibility criteria — including minimum duration of use and timing of diagnosis — are defined within the Master Settlement Agreement. Women who believe they may qualify should consult with a qualified personal injury attorney as soon as possible to assess their eligibility and ensure timely registration before the November 2026 deadline.
Will all pending federal lawsuits be covered by the settlement?
Not necessarily. While the parties estimate that roughly 80 percent of the more than 6,400 pending federal plaintiffs will be eligible to participate, some claimants may not meet the specific eligibility criteria outlined in the Master Settlement Agreement. Additionally, some plaintiffs may choose to opt out of the settlement and pursue individual litigation. Claimants who do not participate in the settlement retain their right to proceed independently, though they will not receive settlement payments and will face a longer and more uncertain litigation path.
What should I do right now if I used Depo-Provera and have a meningioma diagnosis?
Act promptly. With settlement registration expected to close in November 2026, time is limited. Begin by contacting a personal injury attorney with experience in pharmaceutical mass tort litigation who can evaluate your eligibility, help you compile the necessary medical and usage documentation, and ensure your claim is properly submitted before the registration deadline. Do not wait for further public announcements before taking action — the administrative steps required to participate in the settlement take time, and missing the registration window could affect your ability to receive compensation.
James Mitchell is a personal injury legal researcher with over a decade of experience analyzing settlement data and compensation trends across the United States. He has studied thousands of personal injury cases to help injury victims understand their legal rights and the potential value of their claims. James is not an attorney and the information he provides is for
educational purposes only.